Company news

Pharvaris N.V. news in 2024

Pharvaris N.V.'s news releases, calls and decks from 2024, newest first.

View company

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

November 12, 2024

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

November 11, 2024

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

October 23, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

October 15, 2024

Pharvaris to Host Virtual Investor Event on October 23, 2024

October 14, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

October 2, 2024

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

September 4, 2024

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

September 4, 2024

Pharvaris Presents Data at the Bradykinin Symposium 2024

September 4, 2024

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

August 27, 2024

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

June 3, 2024

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 12, 2024

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 9, 2024

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

April 9, 2024

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

April 3, 2024

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

March 17, 2024

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

March 5, 2024

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

March 4, 2024

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

February 21, 2024

Pharvaris Announces Extraordinary Meeting of Shareholders

February 15, 2024

Pharvaris to Present at the WSAAI Annual Meeting 2024

January 25, 2024

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

January 21, 2024

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

January 4, 2024

Decks in 2024